knowledge -WSS

knowledge

author：explore 2025-09-27 18:53:45 - browse：6

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： The lessons of Aduhelm, an Alzheimer's drug that was not to be

explore

WSS

New Ultima Genomics DNA sequencer can read genome for $100

The lessons of Aduhelm, an Alzheimer's drug that was not to be

ReNAgade cuts staff seven months after raising $300 million

What to do when lifesaving products contribute to climate change

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Congressmen charge Covid hearing ‘could have been an email’

knowledge

knowledge

leisure time

Activists slam private health insurers over coverage restrictions

Covid misinformation case heads to Supreme Court

In age of alternative facts, a scholarly course on calling out crap

Despite FDA concern, risk that CAR

Moonlake's readout produced a cash windfall. Risks remain

Flagship Pioneering launches a new biotech in two countries

How one medical school became remarkably diverse

Congressmen charge Covid hearing ‘could have been an email’

In age of alternative facts, a scholarly course on calling out crap

J&J to emphasize cancer drugs, stop much of its vaccine research

entertainment

Organ aging and disease risk measured by new blood test

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

The lessons of Aduhelm, an Alzheimer's drug that was not to be

30 years of 'Listening to Prozac'

Quicker fix for pulse oximeters urged during FDA public meeting

Rep. Raul Ruiz on the physician shortage and more

explore

explore

hotspot

hotspot